Claims
- 1. A block copolymer of formula X, formula Y, or formula Z:
- 2. The copolymer of claim 1 where at least 0.1% of the POE units are of formula II.
- 3. The copolymer of claim 2 where R1 and R2 are both methyl.
- 4. The copolymer of claim 2 where R4 is ethyl.
- 5. The copolymer of claim 2 where p is 1 or 2, and R8 is methyl.
- 6. The copolymer of claim 2 where HO—R6—OH is 1,4-cyclohexanedimethanol.
- 7. The copolymer of claim 2 which is a compound of formula Z.
- 8. The copolymer of claim 7 where h is an integer from 10 to 500, and g and j are independently an integer from 5 to 100.
- 9. The copolymer of claim 1 which is a compound of formula X.
- 10. The copolymer of claim 9 where f is an integer from 10 to 500 and g is an integer from 5 to 100.
- 11. The copolymer of claim 2 where at least 50% of the POE units are of formula II.
- 12. The copolymer of claim 11 where 100% of the POE units are of formula II.
- 13. A micellar pharmaceutical composition for the delivery of a hydrophobic or water-insoluble active agent, comprising the active agent physically entrapped within but not covalently bonded to a drug carrier comprising a block copolymer of claim 1.
- 14. A micellar pharmaceutical composition for the delivery of a hydrophobic or water-insoluble active agent, comprising the active agent physically entrapped within but not covalently bonded to a drug carrier comprising a block copolymer of claim 2.
- 15. The composition of claim 14 where the active agent is an anticancer agent.
- 16. The composition of claim 14 where the active agent is an anti-inflammatory agent.
- 17. A composition for the sustained release of an active agent, comprising the active agent dispersed in a matrix comprising the block copolymer of claim 1.
- 18. A composition for the sustained release of an active agent, comprising the active agent dispersed in a matrix comprising the block copolymer of claim 2.
- 19. The composition of claim 18 where the active agent is an anticancer agent.
- 20. The composition of claim 18 where the active agent is an anti-inflammatory agent.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the priority under 35 USC 119(e) of Provisional Application No. 60/ ______ filed May 11, 2001 (application Ser. No. 09/854,150, filed May 11, 2001, for which a petition to convert to a provisional application was filed on Mar. 29, 2002).
Provisional Applications (1)
|
Number |
Date |
Country |
|
60386201 |
May 2001 |
US |